Welcome to Seacross Pharmaceuticals Ltd.
Oncology Injectable Other Product 1 Other Product 2
Pacltaxel 6 mg/ml

Therapeutic indications: 

Paclitaxel Injection is used to treat:

Ovarian cancer:

• as first therapy (after initial surgery in combination with the platinum-containing medicine cisplatin).

• after standard platinum-containing medicines have been tried but did not work.

Breast cancer:

• as first therapy for advanced disease or disease which has spread to other parts of the body (metastatic disease). Paclitaxel Injection is either combined with an anthracycline (e.g. doxorubicin) or with a medicine called trastuzumab  (for patients for whom anthracycline is not suitable and whose cancer cells have a protein on their surface called HER 2, see package leaflet of trastuzumab).

• after initial surgery following treatment with anthracycline and cyclophosphamide (AC) as an additional treatment.

• as a second-line treatment for patients who have not responded to standard treatments using anthracyclines, or for whom such treatment should not be used.

Advanced non-small-cell lung cancer:

• in combination with cisplatin, when surgery and/or radiation therapy aren’t suitable.

AIDS-related Kaposi's sarcoma:

• where another treatment (i.e. liposomal anthracyclines) has been tried but did not work.

Form Concentrate for solution for infusion
Strength 30mg/5ml, 100mg/16.7ml, 300mg/50ml
Active substance Paclitaxel
Other ingredients Polyoxyl castor oil (macrogolglycerol ricinoleate), citric acid anhydrous and ethanol.
© Copyright - Clinico fusce blandit sapien eu